Bio-Rad Laboratories Inc Class A
BIO: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$973.00 | Gkgp | Swslqfjrz |
Tough Comparables and Foreign Exchange Lead to Bio-Rad Sales Decline; Core Results Meet Expectations
While Bio-Rad’s second-quarter sales decline may seem disappointing, the story of the quarter was like the first quarter in that growth declines were not as bad as feared, and the company maintained margins in the face of inflation headwinds. Our $524 fair value estimate and narrow-moat ratings are unchanged, although we have slightly reduced our top-line forecasts for the year to account for foreign-exchange effects.